Laboratoires Pierre Fabre has received European Commission approval for BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX for first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer. This marks the first and only combination with a BRAF-targeted therapy approved for this indication in the EU. The approval follows results from the Phase 3 BREAKWATER trial, which showed the combination achieved statistically significant improvements in dual primary endpoints. Median progression-free survival reached 12.8 months versus 7.1 months for oxaliplatin-based chemotherapy with or without bevacizumab. The treatment reduced the risk of death by 51% and demonstrated a confirmed objective response rate of 65.7% compared to 37.4% in the control group. The regimen addresses a significant unmet need for patients with limited treatment options.

Laboratoires Pierre Fabre selects Agentforce Life Sciences for Customer Engagement to transform medical and dermo-cosmetic care. CASTRES, France, and SAN FRANCISCO - May 21, 2026 - Laboratoires Pierre Fabre, a major global pharmaceutical and dermo-cosmetics company based in France, has selected Agentforce Life Sciences for Customer Engagement for its more than 4,000 internal users to harmonize its commercial processes across its prescription drug and dermo-cosmetic business lines into a single platform as "One CRM." Building on an existing foundation of Agentforce Service and Data 360, the French company is expanding its Salesforce footprint to break down existing silos between its medical and dermo-cosmetics (OTC) businesses, including global brands such as Eau Thermale Avène or Klorane. The Agentforce 360 Platform will serve as its single, next-generation operating system covering all medical and point-of-sale (POS) related processes across the organization's global operations. This harmonized and regulation-compliant approach will help to ensure consistent and personalized engagement across channels and improve healthcare experiences and access. * Omni-Channel Synergy: Powered by Data 360 and Agenforce Marketing, the company will gain holistic stakeholder views for AI-guided engagement and synchronized interactions across medical and dermo-cosmetics, facilitating personalized journeys for HCPs, key opinion leaders (KOLs), and pharmacies alike. * Personalized Medical Engagement: Agentforce Life Sciences will coach, prepare, and log healthcare visits, updating records to maintain compliance and help to reduce the administrative burden on medical science liaisons (MSLs) and med reps. Through improved content alignment with clinical expectations and a more consistent physical and digital experience, Pierre Fabre aims to improve HCP satisfaction by up to 20%. * Optimized Retail Execution: Agentforce 36O for Life Sciences will help to boost sell-in, maximize sell-out, and drive POS excellence, including rebates, vouchers, and discounting, worldwide. With automated and accurate order management, the dermo-cosmetics leader will improve both care experiences and revenue, taking into account the complexities of country-specific sales rules and pricing structures. Marie-Andrée Gamache, CEO of Pierre Fabre Pharma, explained: "Salesforce will enable us to have a truly customer-centric view by bringing together our two businesses onto a single platform. We will be realizing our vision of a truly harmonized, next-generation operating system. This transformation will allow our teams to act as one cohesive health and dermo-cosmetic player, whether engaging a specialist on oncology therapies or a pharmacist on our dermo-cosmetic products. We chose Agentforce Life Sciences because it provides the robust, proven, and flexible foundation required to simplify our operations while supporting the unique complexity of our global, dual-business model." Emilie Sidiqian, CEO of Salesforce France, added: "We are delighted to partner with Laboratoires Pierre Fabre on this enterprise-wide commercial transformation. This collaboration underscores Agentforce Life Science's market leadership and commitment to delivering the innovative, industry-specific solutions required to meet the evolving needs of global sciences companies. We are proud to provide Laboratoires Pierre Fabre with the trusted platform to break down data silos, enhance customer engagement, and further their mission of improving human health and well-being through their unique blend of prescription medicine and consumer care." About Laboratoires Pierre Fabre. Pierre Fabre Laboratories is the world's second-largest dermo-cosmetics company and one of Europe's leading pharmaceutical laboratories. Its Dermo-cosmetics & Personal Care portfolio brings together major international brands such as Eau Thermale Avène, Dexeryl, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow, and Elgydium. The Pharma activity covers five main therapeutic fields: oncology, dermatology, rare diseases, primary care, and family healthcare. In 2025, Pierre Fabre Laboratories generated 3.2 billion euros in revenue, 71% of which came from international sales across 130 territories. Based in southwest France since its creation and manufacturing nearly 90% of its products in France, Pierre Fabre Laboratories employs 10,000 people worldwide. R&D investments increased by 14% compared with the previous year, reaching 250 million euros, 67% of which is dedicated to targeted therapies in oncology. The majority shareholder of Pierre Fabre Laboratories is the Pierre Fabre Foundation (holding 86.3% of the capital), a humanitarian foundation recognized as being of public utility. The company's employees are its second-largest shareholder (nearly 10%). This shareholding structure guarantees the company's independence, its long-term vision, and its sustainable contribution to the common good. Dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least-developed countries in the world. Since 2023, Pierre Fabre Laboratories' CSR policy has been assessed by AFNOR Certification and has been awarded the "Exemplary" level of its CSR label (ISO 26000 standard for sustainable development). About Salesforce. Salesforce helps organizations of all sizes become Agentic Enterprises, integrating people, agents, applications, and data on a unified, trusted platform to drive unprecedented growth and innovation. Visit www.salesforce.com/fr to learn more. Just for you.